Cemiplimab - Regeneron Pharmaceuticals
Alternative Names: Cemiplimab-rwlc; Libtayo; REGN-2810; SAR-439684Latest Information Update: 20 Jun 2024
At a glance
- Originator Regeneron Pharmaceuticals
- Developer BioNTech; Columbia University; Dana-Farber Cancer Institute; Inovio Pharmaceuticals; ISA Pharmaceuticals; Regeneron Pharmaceuticals; Replimune; Sanofi; SillaJen Biotherapeutics; Sun Pharmaceutical Industries; University of Texas M. D. Anderson Cancer Center; University of Zurich
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Programmed cell death 1 receptor antagonists; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Basal cell cancer; Non-small cell lung cancer; Squamous cell cancer
- Registered Cervical cancer
- Phase III Malignant melanoma
- Phase II Glioblastoma; Haemangiosarcoma; Head and neck cancer; Liver cancer; Oropharyngeal cancer; Prostate cancer
- Phase I/II Fallopian tube cancer; Multiple myeloma; Ovarian cancer; Peritoneal cancer; Solid tumours
- No development reported B-cell lymphoma; Cancer; Haematological malignancies; Renal cell carcinoma
Most Recent Events
- 07 Jun 2024 Phase-II clinical trials in Non-small cell lung cancer (Newly diagnosed, Early-stage disease, Combination therapy) in USA (IV) (EudraCT2023-505172-29-00) (NCT06161441)
- 31 May 2024 Efficacy and adverse events data from a phase-II trial in cervical cancer presented at the 60th Annual Meeting of the American Society of Clinical Oncology (ASCO-2024)
- 31 May 2024 Adverse events and efficacy data from a phase II trial in Oropharyngeal cancer presented at the 60th Annual Meeting of the American Society of Clinical Oncology (ASCO-2024)